Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

CN470 is a BET/CBP/p300 multi-bromodomain inhibitor and has an anti-tumor activity against MLL-rearranged acute lymphoblastic leukemia

Biochemical and Biophysical Research Communications(2021)10.1016/j.bbrc.2021.12.078Source: DataRank Database

CN470 is a BET/CBP/p300 multi-bromodomain inhibitor and has an anti-tumor activity against MLL-rearranged acute lymphoblastic leukemia is a research paper published in Biochemical and Biophysical Research Communications (2021). On theSindex it has a DataRank of 0. It has been cited 14 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access14 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (7 grants)Impact (FWCI 0.81)OA: greenTopics (58)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (14)

Makoto Yoshioka ORCID,Kuniaki Tanaka,Shyh‐Ming Yang ORCID,Koshi Akahane ORCID,Yuki Toda

Live enrichment

PubMed:34971957 PMC:PMC8898544 OpenAlex:https://openalex.org/W4200154849

Japan Society for the Promotion of Science

Grant: 20J22374

Ministry of Education, Culture, Sports, Science and Technology

Grant: 19K08826

Ministry of Education, Culture, Sports, Science and Technology

Grant: S1511024L

Intramural NIH HHS

Grant: Z99 TR999999

National Center for Advancing Translational Sciences

Takeda Science Foundation

National Institutes of Health

FWCI

0.81

Citation Percentile

0.7%

Citation Trend

2022

2023

2024

2025

2026

greenLicense: https://doi.org/10.15223/policy-004

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/8898544

publisherhttps://api.elsevier.com/content/article/PII:S0006291X21017198?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0006291X21017198?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.bbrc.2021.12.078

Fields of Study

Protein Degradation and InhibitorsMultiple Myeloma Research and TreatmentsUbiquitin and proteasome pathwaysAnimalsAntineoplastic AgentsApoptosisCell Cycle CheckpointsCell Line, TumorCell ProliferationE1A-Associated p300 ProteinGene Expression Regulation, LeukemicGene RearrangementHistone-Lysine N-MethyltransferaseHumansMiceMyeloid-Lymphoid Leukemia ProteinPrecursor Cell Lymphoblastic Leukemia-LymphomaRNA, MessengerSurvival AnalysisXenograft Model Antitumor Assays

MeSH Terms

AnimalsAntineoplastic AgentsHumansHistone-Lysine N-MethyltransferaseRNA, MessengerGene RearrangementGene Expression Regulation, LeukemicSurvival AnalysisApoptosisXenograft Model Antitumor AssaysCell Line, TumorCell ProliferationE1A-Associated p300 ProteinMiceMyeloid-Lymphoid Leukemia ProteinPrecursor Cell Lymphoblastic Leukemia-LymphomaCell Cycle Checkpoints

Keywords

BromodomainBRD4Cancer researchBET inhibitorIn vivoLeukemiaCell cycleBiologyMolecular biologyAcetylationApoptosisChemistryGeneImmunologyBiochemistryGeneticsBETCBP/p300AllMllPdx

Sustainable Development Goals

SDG 0: Good health and well-being